Chelsea and Westminster Hospital
NHS Foundation Trust

Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group

Summary of Main Points from the Meeting held on Monday 10th June 2024

2. Minutes and Summary Notes from last meeting

This meeting was held via Teams. The Minutes and Summary notes of the Medicines Group Meeting held on 26th February 2024 were approved. The summary notes will be disseminated and published on the Trust intranet. A quarterly summary report will be drafted and forwarded to the Trust Patient Safety Group meeting for inclusion on the agenda in due course.

3. Matters Arising

The Group noted the matters arising from the previous meeting.

4. Business to be transacted by the Medicines Group

4.1 Formulary Applications

Full Applications

- **Rezafungin 200mg Infusion**

Requested by: Microbiology
Indication: Candidaemia
Proposal: Add to the formulary for prescribing in line on recommendation by the Microbiology Team its licensed indication
Rational: Administered weekly and therefore reduces daily administration of alternative antifungals
Cost: £3,360 per 4-week course (PbREx as funded by NHS England)
Likely to treat: 1-2 patients per year at both hospital sites
Outcome: Approved for addition to the formulary

Support of service expansion proposal at Chelsea and Westminster Hospital Trust for the treatment of Non-Tubercular Mycobacteria (NTM) infections:

- **Amikacin Liposomal Inhalation Suspension (ALIS) (Arikayce®)**

Requested by: Microbiology
Indication: Treatment of Non-tuberculous lung disease due to *Mycobacterium Avium Complex* (MAC)
Proposal: Add to the formulary for prescribing in line on recommendation by the Microbiology Team its licensed indication
Rational: To support the Trust become a Non-Tubercular Mycobacteria (NTM) Specialist Centre
Cost: PbREx as funded by NHS England
Likely to treat: 3 patients per year at CWH Site
Outcome: Approved for addition to the formulary

- **Azithromycin 500mg IV**

Requested by: Microbiology
Indication: Treatment of Non-tuberculous lung disease due to *Mycobacterium Avium Complex* (MAC)
Proposal: Add to the formulary for prescribing in line on recommendation by the Microbiology Team its licensed indication
Rational: To support the Trust become a Non-Tubercular Mycobacteria (NTM) Specialist Centre
Cost: £9.50 per 500mg vial - Recent contract changes make this more cost effective comparator to other IV macrolides
Likely to treat: 3 patients per year at CWH Site
Outcome: Approved for addition to the formulary

- **Cefoxitin 1g IV (Renoxitin®)**

Requested by: Microbiology
Indication: Treatment of Non-tuberculous lung disease due to *Mycobacterium Avium Complex* (MAC)
Proposal: Add to the formulary for prescribing in line on recommendation by the Microbiology Team its licensed indication

Rational: Provide anti-NTM treatment for complex infection (as alternative to Imipenem)
Cost: Individual patient costs of £6k per 3 month course expected (dependent on dose). Usage will be restricted by ID / AMS team to cases where nil alternative exists; this is a cost pressure to alternative 1st line IV imipenem (£5.4k per 3 month course)
Likely to treat: 3 patients per year at CWH Site
Outcome: Approved for addition to the formulary

Ex-Panel

- **Ivermectin 3mg Tablets**

Requested by: GUM
Indication: Hyperkeratotic (i.e. crusted) Scabies that does not respond to first-line treatments
Proposal: Add to the formulary for prescribing in line with its licensed indication
Rational: To replace unlicensed product. Ivermectin is now licensed in the UK, therefore CWFT should move to procuring and issuing the licensed product
Cost: Supplied by Exeltis at £49.20 ex VAT (£59.04 inc VAT) for 3mg x 4 tab pack
Cost comparison with unlicensed product:
Unlicensed imported product: £65.20 for 3mg x 4 tab (via Mawdsley as a Special)
Likely to use: 600 x 4 x 3mg tablet packs
Based on usage in 2023/24 with 20% increase
Outcome: Approved for addition to the formulary

- **Pantoprazole 20mg & 40mg Tablets**

Requested by: Gastroenterology
Indication: PPI
Proposal: Add to the formulary for prescribing in line with its licensed indication
Rational: IV Formulation is currently included on the CWFT Formulary but not the oral formulation
Oral formulations are currently included on the North West London Joint Formulary and as a result many patients are being admitted to hospital taking this medicine. Ideally if this was to be included on the CWFT formulary this would reduce the need to switch PPIs as patients are admitted.
Similar in cost to the 1st and 2nd line PPIs used in the Trust.
Cost: Pantoprazole: £0.47 for 20mg x 28 & £0.61 for 40mg x 28
Cost comparison with other PPIs included on the formulary:
Omeprazole: £0.41 for 10mg x 28 & £0.32 for 20mg x28
Lansoprazole: £0.42 for 15mg x 28 & £0.95 for 30mg x 28
Likely to use: A proportion of the 1,500 packs that are issued of the other PPIs included on the formulary.
Outcome: Approved for addition to the formulary

- **Bibecfo 200micrograms/6micrograms/dose MDI Inhaler**

Requested by: Respiratory Team supported by NWL ICB
Indication: Maintenance therapy in Asthma
Proposal: Add to the formulary for prescribing in line with its licensed indication
Rational: Bibecfo® is a generic form of Fostair®. Fostair® is one of the most commonly prescribed inhalers in the Trust used in the management of patients with Asthma. Bibecfo® is a like-for-like equivalent to Fostair® and costs considerably less.

- Fostair® 200/6 pMDI: £29.32/30 days
- Bibecfo® 200/6 pMDI: £13.98/30 days

If 50% of all prescriptions for Fostair® 100/6 and 200/6 MDIs, and generically written beclometasone dipropionate/ formoterol MDI in NWL are changed to Fostair NEXThaler® (cost neutral) and the remaining 50% to Bibecfo® MDI, the approximate cost saving is £1,225,000 per year (primary care).
Cost: See above
Likely to use: Estimate of 3000 inhalers/annum
Outcome: Approved for addition to the formulary

- **Rivaroxaban (Xarelto®) 1mg/ml granules for oral suspension**

Requested by: Paediatrics
Indication: In line with licensed use:

- Treatment of venous thromboembolism,

- Prophylaxis of recurrent venous thromboembolism

Proposal: Add to the formulary for prescribing in line with its licensed indication.
Rational: Issuing to paediatric patient or adults who cannot swallow tablets or where the required dosage cannot be delivered by means of tablets
Cost:
100mL bottle = £9 (BNF)
250mL bottle = £18 (BNF)
Likely to use: 10-30 bottles per year
Outcome: Approved for addition to the formulary

Removals

- **Gentisone HC ear drop**
- **Didanosine 125mg EC capsule (Videx®)**
- **Didanosine 200mg EC capsule (Videx®)**
- **Didanosine 250mg EC capsule (Videx®)**
- **Didanosine 400mg EC capsule (Videx®)**
- **Didanosine 200mg tablet (Videx®)**
- **Didanosine suspension (Videx®)**
- **Stavudine 20mg capsule (Zerit®)**
- **Stavudine 30mg capsule (Zerit®)**
- **Stavudine 40mg capsule (Zerit®)**
- **Stavudine 1mg/ml oral solution (Zerit®)**
- **Calcitonin (Salmon) 50unit/ml Injection (Salcitonin®)**
- **Calcitonin (Salmon) 400unit/ml Injection (Salcitonin®)**
- **Mesalazine 400mg EC tablet (Asacol®)**

All discontinued by the manufacturer
Outcome: Approved for removal from the formulary

NICE Approved drug applications

- **TA924 - Tirzepatide for treating Type 2 Diabetes (25/10/2023)**

Proposal: Add to the formulary in line with NICE TA924
Outcome: Approved for addition to the formulary

- **TA947 - Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments (31/01/2024)**

Proposal: Add to the formulary in line with NICE TA947
Outcome: Approved for addition to the formulary

- **TA950 - Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over (07/02/2024)**

Proposal: Add to the formulary in line with NICE TA950
Outcome: Approved for addition to the formulary

- **TA952 - Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (21/02/2024)**

Proposal: Add to the formulary in line with NICE TA952
Outcome: Approved for addition to the formulary

- **TA954 - Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (06/03/2024)**

Proposal: Add to the formulary in line with NICE TA954
Outcome: Approved for addition to the formulary

- **TA956 - Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 years and over (11/03/2024)**

Proposal: Add to the formulary in line with NICE TA956
Outcome: Approved for addition to the formulary

- **TA957 - Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (20/03/2024)**

Proposal: Add to the formulary in line with NICE TA957
Outcome: Approved for addition to the formulary

- **TA958 - Ritlecitinib for treating severe alopecia areata in people 12 years and over (27/03/2024)**

Proposal: Add to the formulary in line with NICE TA958
Outcome: Approved for addition to the formulary

- **TA973 - Atogepant for preventing migraine (15/05/2024)**

Proposal: Add to the formulary in line with NICE TA973
Outcome: Approved for addition to the formulary

Pharmacoeconomic Board requests

- **Infliximab for Sarcoidosis**

Approved by Pharmacoeconomic Board on 27/03/2024
Outcome: Noted

- **Secukinumab for Ankylosing Spondylitis (Approved 28/03/2024)**

Approved by Pharmacoeconomic Board on 28/03/2024
Outcome: Noted

- **Rezafungin for recurrent oesophageal candidiasis (Approved: 10/05/2024)**

Approved by Pharmacoeconomic Board on 10/05/2024
Outcome: Noted

4.2 Trust Medicines Policy and IV Administration Guides

- **TMP: Section 24 - Concentrated Potassium Solutions**

Routine review and update
- Update to the list of preparations that are classed and stocked as “Concentrated Potassium Solutions” within the Trust.
- Update to the list of potassium containing products stocked in Pharmacy
- Update to the list of clinical areas that stock “Concentrated Potassium Solutions” within the Trust.
- Addition of requirement for any clinical area that stocks a “Concentrated Potassium Solution” to have a Risk Assessment in place that has been ratified by The Trust Patient Safety Group.

Outcome: Approved

- **Options appraisal for updating the Trust Adult IV Administration Guide**

Decision to be made regarding optimal approach to be take including:
- Option 1: Do nothing
- Option 2: Use unannotated version of Medusa
- Option 3: Create an annotated version of Medusa (Preferred option)

Outcome: Option 3 approved for taking forward

- **Trust Paediatric and Neonatal IV Administration Guide**

Full review and update of guide
- Rocuronium infusion added
- Insulin infusion updated to include a new multiplication factor
- Pancuronium and THAM removed as product no longer available

Outcome: Approved with 1 year expiry

4.3 Medicines Optimisation

- **Guideline for medical and pharmacy staff managing patients on lithium therapy at Chelsea and Westminster Hospital (Cross-site)**

New cross-site guideline for the management of patients admitted taking Lithium therapy
Written in collaboration with the Pharmacy, CNWL Liaison Psychiatry Team and Hounslow Liaison Psychiatry Team
This is a cross-site policy for use across both hospital sites
Outcome: Approved

- **Guideline for the topical treatments for in-patient with dermatological conditions (Cross-site)**

Reviewed and updated guideline.
This guidelines been drafted with input from the following key stakeholders:
- Adult Dermatology
- Paediatric Dermatology
- Pharmacy

Outcome: Approved pending resolution of two minor queries which were resolved post-meeting.

4.4 NICE Technical Appraisals and Guidance

a) NICE Technology Appraisals published

24 TA published since previous TMG meeting

TA952 - Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (21/02/2024)
Formulary status / Action
Not included on the formulary
Application form received - See Section 4.1

TA953 - Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (13/03/2024)
Formulary status / Action
Included on the formulary for another indication
Numbers likely to treat at CWH site: 5 patients per year
Numbers likely to treat at WMUH site: 0 patient per year

TA954 - Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (06/03/2024)
Formulary status / Action
Not included on the formulary
Application form received - See Section 4.1

TA955 - Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (13/03/2024)
Formulary status / Action
Nil - Not recommended

TA956 - Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over (11/03/2024)
Formulary status / Action
Not included on the formulary
Application form received - See Section 4.1

TA957 - Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (20/03/2024)
Formulary status / Action
Not included on the formulary
Application form received - See Section 4.1
TA958 - Ritlecitinib for treating severe alopecia areata in people 12 years and over (27/03/2024)
Formulary status / Action

Not included on the formulary
Application form received - See Section 4.1

TA959 - Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis (27/03/2024)
Formulary status / Action
Included on the formulary for another indication
Numbers likely to treat at CWH site: 1-2 patients per year
Numbers likely to treat at WMUH site: 1-2 patients per year

TA960 - Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal) (27/03/2024)
Formulary status / Action
Nil - Terminated Appraisal

TA961 - Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal) (28/03/2024)
Formulary status / Action
Nil - Terminated Appraisal

TA962 - Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (28/03/2024)
Formulary status / Action
Included on the formulary for another indication
Action: Nil as condition not treated at CWFT.

TA963 - Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (03/04/2024)
Formulary status / Action
Not included on the formulary
Action: Nil as condition not treated at CWFT.

TA964 - Cabozantinib with nivolumab for untreated advanced renal cell carcinoma (10/04/2024)
Formulary status / Action
Included on the formulary for another indication
Numbers likely to treat at CWH site: 3 patients per year
Numbers likely to treat at WMUH site: 0 patient per year

TA965 - Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal) (28/03/2024)
Formulary status / Action
Nil - Terminated Appraisal

TA966 - Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (Terminated appraisal) (24/04/2024)
Formulary status / Action
Nil - Terminated Appraisal

TA967 - Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over (01/05/2024)
Formulary status / Action
Included on the formulary for another indication
Numbers likely to treat at CWH site: 1-3 patients per year
Numbers likely to treat at WMUH site: 1-3 patients per year

TA968 - Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (Terminated appraisal) (25/04/2024)

Formulary status / Action

Nil - Terminated Appraisal

TA969 - Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal) (30/04/2024)
Formulary status / Action
Nil - Terminated Appraisal
TA970 - Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments (08/05/2024)
Formulary status / Action
Not included on the formulary
Action: Add to the formulary following receipt of an application form from the Haematology Department

TA971 - Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (08/05/2024)
Formulary status / Action
Included on the formulary
Numbers likely to treat at CWH site: 30 patients per year
Numbers likely to treat at WMUH site: 30 patients per year

TA972 - Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (Terminated Appraisal) (22/05/2024)
Formulary status / Action
Nil - Terminated Appraisal

TA973 - Atogepant for preventing migraine (15/05/2024)
Formulary status / Action
Not included on the formulary
Application form received - See Section 4.1

TA974 - Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma (15/05/2024)
Formulary status / Action
Not included on the formulary
Action: Add to the formulary following receipt of an application form from the Haematology Department

TA975 - Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under (15/05/2024)
Formulary status / Action
Not included on the formulary
Action: Nil as condition not treated at CWFT.

b) NICE Highly Specialised Technology Appraisals published since previous TMG meeting

0 HST Appraisals published since previous TMG meeting

4.5 Items for noting

- **Quarterly Controlled Drug Summary Report - Q3 2023/24**

Quarterly Controlled Drug Summary Report for Q3 2023/24
3 x Incidents escalated to NHS England
Outcome: Noted

- **Quarterly Controlled Drugs Accountable Officer Report - Q3 2023/24**

Quarterly CD Accountable Officer Report for Q3 2023/24
Outcome: Noted

- **Trust Medicines Group Report for Patient Safety - April 2024**

Trust Medicines Group report to Trust Patient Safety Group - April 2024
Outcome: Noted

- **Medication Safety Bulletin: Medicines management and storage**

Medication Safety Bulletin relating to Medicines management and storage
Outcome: Noted

- **Medication Safety Bulletin: Duplicate Medications**

Medication Safety Bulletin relating to Duplicate Medications
Outcome: Noted

- **Medication Safety Bulletin: Look Alike / Sound Alike**

Medication Safety Bulletin relating to Look Alike / Sound Alike
Outcome: Noted

- **MHRA Drug Safety Update - March 2024**

MHRA update for March 2024
Outcome: Noted

- **MHRA Drug Safety Update - April 2024**

MHRA update for April 2024
Outcome: Noted

4.6 Meeting minutes for noting

- **Antimicrobial Stewardship Group meeting minutes - January 2024**

Minutes from Medication Safety Group Meeting held January 2024
Outcome: Noted

- **HIV/GUM Medicines Sub-Group Meeting - October 2023**

Minutes from HIV/GUM Medicines Sub-Group Meeting held October 2023
Outcome: Noted

- **HIV/GUM Medicines Sub-Group Meeting - January 2024**

Minutes from HIV/GUM Medicines Sub-Group Meeting held January 2023
Outcome: Noted

- **HIV, Sexual Health and Gender Health Medicines Sub-Group Meeting**

Minutes from HIV, Sexual Health and Gender Health Medicines Sub-Group Meeting - April 2024
Outcome: Noted

- **HIV, Sexual Health and Gender Health Medicines Sub-Group Meeting - Terms of Reference - April 2024**

Terms of Reference for HIV, Sexual Health and Gender Health Medicines Sub-Group
Outcome: Approved

5. Any other business

- **Nil**

6. Date of next meeting

Next meeting
Day: Monday
Date: September 16th 8-9am (Note: Subject to change due to staff AL)
Time: 8am-9am
Location: via Teams